Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q86VP1
UPID:
TAXB1_HUMAN
Alternative names:
TRAF6-binding protein
Alternative UPACC:
Q86VP1; A4D196; B4DKU7; E7ENV2; O60398; O95770; Q13311; Q9BQG5; Q9UI88
Background:
Tax1-binding protein 1, also known as TRAF6-binding protein, plays a pivotal role in immune response regulation. It is involved in inflammatory, antiviral, and innate immune processes, as well as selective autophagy. This protein acts as an adapter for the ubiquitin-editing enzyme A20/TNFAIP3, crucial for inactivating substrates and regulating NF-kappa-B and IRF3 signaling pathways. It also plays a role in inhibiting virus-induced apoptosis and facilitating the clearance of pathogenic bacteria.
Therapeutic significance:
Understanding the role of Tax1-binding protein 1 could open doors to potential therapeutic strategies.